![]() To date, we have been able to balance supply and demand through careful management. The supply chain constraints highlighted in our Q2 call, however, have persisted in particular, for supply and cost of plastic raw materials, electronic components and higher logistics costs. Our end markets continued to show improvement during Q3, with demand pickup in both life science and diagnostic markets in all regions. We're now entering the seventh consecutive quarter of operating within the COVID pandemic and so I shall make my comments brief as we have now established an operating cadence with embedded employee safety practices. Now, I'd like to take a few minutes to review our current state of operations around the world. Annette's efforts and leadership have contributed to significant growth for the Life Science Group and Bio-Rad and the company has started a search for a successor and we will provide an update in the coming months. To start with, I'd like to take a moment to thank Annette Tumolo, our President of the Life Science Group for nearly 33 years of service at Bio-Rad as she plans to retire at the end of this year. Before I begin the detailed third quarter discussion, I would like to ask Andy Last, our Chief Operating Officer, to provide an update on Bio-Rad's operations in light of the current pandemic-related environment that we are experiencing globally. Thank you all for joining us and we hope that you and your families are well and staying healthy during these challenging times. With that, I now turn over the call to Ilan Daskal, our Executive Vice President and Chief Financial Officer. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share which are our financial measures that are not defined under generally accepted accounting principles. The company does not intend to update any forward-looking statements made during the call today. You should not place undue reliance on these forward-looking statements and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. Our actual results may differ materially from these plans and expectations and the impact and duration of the COVID-19 pandemic is unknown. Included in these forward-looking statements are a commentary regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. With me on the phone today are Norman Schwartz, our Chief Executive Officer Ilan Daskal, Executive Vice President and Chief Financial Officer Andy Last, Executive Vice President and Chief Operating Officer Annette Tumolo, President of the Life Science Group and Dara Wright, President of the Clinical Diagnostics Group.īefore we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and exceptions - expectations, our future financial performance and other matters. ![]() We will review the third quarter 2021 financial results and provide an update on key business trends for Bio-Rad. Good afternoon and thank you all for joining us today. Edward Chung, Head of Investor Relations. ![]() ![]() I would now like to turn the conference call over to your host, Mr. My name is Lydia and I'm your operator today. Good afternoon, ladies and gentlemen and welcome to the Third Quarter 2021 Bio-Rad Laboratories, Inc. Norman Schwartz - Chief Executive Officerĭara Wright - President of Clinical Diagnostics Group Ilan Daskal - Executive Vice President & Chief Financial OfficerĪndrew Last - Executive Vice President & Chief Operating OfficerĪnnette Tumolo - President of Life Science Group ![]() ( NYSE: BIO) Q3 2021 Earnings Conference Call Octo5:00 PM ETĮdward Chung - Head of Investor Relations ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |